Literature DB >> 12945932

Splenic histology and histopathology: an update.

Madeleine D Kraus1.   

Abstract

The spleen can be a troublesome specimen for the surgical pathologist, not only because experience with the range of "normal" splenic histology is limited by its rarity but also because there is an often a frustrating discordance between the patient's clinical condition and the perceived findings. Patients with a dramatic clinical presentation that points to splenic pathology ("hypersplenism" or marked splenomegaly) not infrequently have no discernable or have barely perceptible histologic abnormalities of the spleen. Similarly, patients whose spleens contain histologic findings that seem to deviate significantly from the "norm" (histiocytic proliferations, vasoformative lesions, stromal hyperplasia) may have no clinically detectable hematologic complaints. For most pathologists, the frame of reference for normal splenic histomorphology derives largely from experience with autopsy spleens and spleens removed for trauma or immune thrombocytopenia. These are all settings in which pre-existing disease, the immune status of the patient, and therapy influence the findings and--in cases in which fixation has been delayed--even the ability to make the findings. This review presents practical aspects of splenic development and immunoarchitecture and relates this to the pathologist's approach in evaluating the abnormal spleen and assists in resolving such discordances. Benign conditions that contrast with the subjects of subsequent articles in this issue are emphasized.

Entities:  

Mesh:

Year:  2003        PMID: 12945932     DOI: 10.1016/s0740-2570(03)00024-8

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  8 in total

1.  Changes in count and function of splenic lymphocytes from patients with portal hypertension.

Authors:  Zong-Fang Li; Shu Zhang; Gao-Bo Lv; Ying Huang; Wei Zhang; Song Ren; Jun Yang; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

2.  Intrapancreatic accessory spleen: utilization of fine needle aspiration for diagnosis of a potential mimic of a pancreatic neoplasm.

Authors:  Tara A Saunders; Theodore R Miller; Elham Khanafshar
Journal:  J Gastrointest Oncol       Date:  2016-04

Review 3.  Diagnosis of intrapancreatic accessory spleen by endoscopic ultrasound-guided fine-needle aspiration mimicking a pancreatic neoplasm: a case report and review of literature.

Authors:  Anas Renno; Michael Hill; Yousef Abdel-Aziz; Hany Meawad; Amanda Lenhard; Ali Nawras
Journal:  Clin J Gastroenterol       Date:  2019-09-23

4.  [Lymphomas of the spleen].

Authors:  A Marx; H K Müller-Hermelink; M Hartmann; E Geissinger; A Zettl; P Adam; T Rüdiger
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

5.  Immunomodulatory effect of Schisandra polysaccharides in cyclophosphamide-induced immunocompromised mice.

Authors:  Jiahui Yu; Lixin Cong; Chunmei Wang; He Li; Chengyi Zhang; Xingang Guan; Peng Liu; Yu Xie; Jianguang Chen; Jinghui Sun
Journal:  Exp Ther Med       Date:  2018-04-16       Impact factor: 2.447

6.  Modulating effects of the synergistic combination of extracts of herbal drugs on cyclophosphamide-induced immunosuppressed mice.

Authors:  Abida Parveen; Sultan Zahiruddin; Nidhi Agarwal; Muhammad Akhtar Siddiqui; Shahid Husain Ansari; Sayeed Ahmad
Journal:  Saudi J Biol Sci       Date:  2021-07-01       Impact factor: 4.219

7.  Effects of Shrimp Peptide Hydrolysate on Intestinal Microbiota Restoration and Immune Modulation in Cyclophosphamide-Treated Mice.

Authors:  Asif Iqbal Khan; Ata Ur Rehman; Nabeel Ahmed Farooqui; Nimra Zafar Siddiqui; Qamar Ayub; Muhammad Noman Ramzan; Liang Wang; Yi Xin
Journal:  Molecules       Date:  2022-03-06       Impact factor: 4.411

8.  Laparoscopic spleen-preserving pancreatic resection for intrapancreatic accessory spleen: Case report.

Authors:  Le Li; Xiaohua Liu; Jinming Chen; Zhonghua Liu; Qiang Li; Ying Shi
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.